ATE188608T1 - Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität - Google Patents

Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität

Info

Publication number
ATE188608T1
ATE188608T1 AT97928360T AT97928360T ATE188608T1 AT E188608 T1 ATE188608 T1 AT E188608T1 AT 97928360 T AT97928360 T AT 97928360T AT 97928360 T AT97928360 T AT 97928360T AT E188608 T1 ATE188608 T1 AT E188608T1
Authority
AT
Austria
Prior art keywords
lofexidine
loss
concentration
treatment
production
Prior art date
Application number
AT97928360T
Other languages
English (en)
Inventor
Amy Arnsten
Keith Davies
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE188608T1 publication Critical patent/ATE188608T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AT97928360T 1996-06-25 1997-06-24 Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität ATE188608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613243.6A GB9613243D0 (en) 1996-06-25 1996-06-25 Attention deficit hyperactive disorder
PCT/GB1997/001713 WO1997049396A1 (en) 1996-06-25 1997-06-24 Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder

Publications (1)

Publication Number Publication Date
ATE188608T1 true ATE188608T1 (de) 2000-01-15

Family

ID=10795815

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97928360T ATE188608T1 (de) 1996-06-25 1997-06-24 Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität

Country Status (7)

Country Link
EP (1) EP0896536B1 (de)
AT (1) ATE188608T1 (de)
AU (1) AU715790B2 (de)
DE (1) DE69701139T2 (de)
ES (1) ES2142169T3 (de)
GB (2) GB9613243D0 (de)
WO (1) WO1997049396A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
EP2334297A1 (de) * 2008-08-08 2011-06-22 Agean Llc Lofexidin-enantiomere zur behandlung von zns-erkrankungen und pathologien und ihre chirale synthese

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800209A (en) * 1981-12-14 1989-01-24 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US4382946A (en) * 1981-12-14 1983-05-10 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
GB9713344D0 (en) 1997-08-27
EP0896536A1 (de) 1999-02-17
GB9613243D0 (en) 1996-08-28
EP0896536B1 (de) 2000-01-12
AU715790B2 (en) 2000-02-10
DE69701139T2 (de) 2000-09-28
WO1997049396A1 (en) 1997-12-31
GB2318976B (en) 1999-10-13
DE69701139D1 (de) 2000-02-17
AU3268497A (en) 1998-01-14
GB2318976A (en) 1998-05-13
ES2142169T3 (es) 2000-04-01

Similar Documents

Publication Publication Date Title
ATE275948T1 (de) Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung
DE59205846D1 (de) Azaheterocyclylmethyl-chromane als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE122005000011I1 (de) Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
SE9102979D0 (sv) Saett att behandla avloppsvatten
DE50310078D1 (de) Verwendung von 2,6-di-tert.-butyl-p-kresol zur erh
HK1073844A1 (en) Method for the production and purification of 1,7' - dimethyl - 2'- propyl - 2,5'- bi-1h-benzimidazole
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
IL177286A0 (en) Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing same
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE198588T1 (de) Der gebrauch von dialdehyden und hieraus erhaltene acetaten zur inhibierung der peroxidzersetzung in der herstellung und behandlung von zurückgewonnener faserpulpe und anderer faserpulpe
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE188608T1 (de) Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität
ATE413416T1 (de) Verfahren zur herstellung von niedermolekularem heparin
DE59503194D1 (de) Verfahren zur herstellung von stärkeabbauprodukten
NO20012854L (no) Fremgangsmåte for avvanning av organiske v¶sker
ATE252392T1 (de) Verwendung des lysozym-dimers zur herrstellung eines arzneimittels zur modulation der naturlichen abwehrvorgänge.
ATE69163T1 (de) Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen.
DE60007103D1 (de) Verfahren zur Förderung der Aufnahme von Nährstoffen, Wasser und/oder Sauerstoff in die Haut
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE60313785D1 (de) Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen.
KR910008138A (ko) 효소법에 의한 l-세린의 제조법

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties